dsip peptide delta sleep-inducing peptide Recombinant Human Delta-Sleep Inducing (dSIP), Cat#RPU41168 Repost @peptides with @use.repost ・・・

DUSP1 (MKP1, PTPN10) DUSP1 (also named MAPK phosphatase 1, MKP1 or protein tyrosine phosphatase non-receptor type 10, PTPN10) functions as a negative regulator of MAPKs by dephosphorylating ERK, JNK, and p38 [36, 54, 55]

Conservative combination protocol (if attempting) Rationale for conservative approach: No safety data available Both peptides slow gastric emptying significantly Risk of severe GI complications Start low, go slow principle Tirzepatide component: Follow standard FDA-approved titration Weeks 1-4: 2.5mg weekly Weeks 5-8: 5mg weekly Weeks 9-12: 7.5mg weekly Weeks 13-16: 10mg weekly Week 17+: 12.5mg weekly (or stay at 10mg) Some reach 15mg weekly (maximum) Cagrilintide component (reduced from standard): Start AFTER tirzepatide stabilized at therapeutic dose (week 13+) Week 13-16: 0.6mg weekly (lower than standard) Week 17-20: 1.2mg weekly Week 21-24: 1.8mg weekly (may be maximum tolerable) Consider 2.4mg only if tolerating perfectly Conservative dosing comparison: Why sequential is safer: Tirzepatide establishes baseline first Can attribute new side effects to cagrilintide Easier to manage one variable at a time Option to stop cagrilintide if intolerable Less overwhelming than both simultaneously Expected benefits: 18-25% total weight loss (conservative estimate) Potentially superior to tirzepatide alone (15-22%) But incremental benefit may be modest (3-5% additional) Use SeekPeptides to plan sequential peptide additions safely

Journal of Environmental Management, 37 , 123587

Xu JC, Xiao MF, Jakovcevski I, Sivukhina E, Hargus G, Cui YF, et al